Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials

BACKGROUND: Nowadays, canagliflozin monotherapy, or in combination with other oral hypoglycemic agents (OHAs), is often administered in patients who are treated for type 2 diabetes mellitus (T2DM). Therefore, we aimed to systematically compare the adverse drugs events (AEs) which were associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bundhun, Pravesh Kumar, Janoo, Girish, Huang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392384/
https://www.ncbi.nlm.nih.gov/pubmed/28411624
http://dx.doi.org/10.1186/s40360-017-0126-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392384/
https://www.ncbi.nlm.nih.gov/pubmed/28411624
http://dx.doi.org/10.1186/s40360-017-0126-9

Ejemplares similares